tetano
Editor, Senior Moderator
Crit Care
. 2021 Aug 19;25(1):299.
doi: 10.1186/s13054-021-03729-9.
Continuous renal replacement therapy in COVID-19-associated AKI: adding heparin to citrate to extend filter life-a retrospective cohort study
Eduardo de Oliveira Valle[SUP] 1 [/SUP], Carla Paulina Sandoval Cabrera[SUP] 1 [/SUP], Claudia Coimbra César de Albuquerque[SUP] 1 [/SUP], Giovanio Vieira da Silva[SUP] 1 [/SUP], Márcia Fernanda Arantes de Oliveira[SUP] 1 [/SUP], Gabriel Teixeira Montezuma Sales[SUP] 1 [/SUP], Igor Smolentzov[SUP] 1 [/SUP], Bernardo Vergara Reichert[SUP] 1 [/SUP], Lucia Andrade[SUP] 1 [/SUP], Victor Faria Seabra[SUP] 1 [/SUP], Paulo Ricardo Gessolo Lins[SUP] 1 [/SUP], Camila Eleuterio Rodrigues[SUP] 2 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease 2019 (COVID-19) may predispose patients to thrombotic events. The best anticoagulation strategy for continuous renal replacement therapy (CRRT) in such patients is still under debate. The purpose of this study was to evaluate the impact that different anticoagulation protocols have on filter clotting risk.
Methods: This was a retrospective observational study comparing two different anticoagulation strategies (citrate only and citrate plus intravenous infusion of unfractionated heparin) in patients with acute kidney injury (AKI), associated or not with COVID-19 (COV + AKI and COV - AKI, respectively), who were submitted to CRRT. Filter clotting risks were compared among groups.
Results: Between January 2019 and July 2020, 238 patients were evaluated: 188 in the COV + AKI group and 50 in the COV - AKI group. Filter clotting during the first filter use occurred in 111 patients (46.6%). Heparin use conferred protection against filter clotting (HR = 0.37, 95% CI 0.25-0.55), resulting in longer filter survival. Bleeding events and the need for blood transfusion were similar between the citrate only and citrate plus unfractionated heparin strategies. In-hospital mortality was higher among the COV + AKI patients than among the COV - AKI patients, although it was similar between the COV + AKI patients who received heparin and those who did not. Filter clotting was more common in patients with D-dimer levels above the median (5990 ng/ml). In the multivariate analysis, heparin was associated with a lower risk of filter clotting (HR = 0.28, 95% CI 0.18-0.43), whereas an elevated D-dimer level and high hemoglobin were found to be risk factors for circuit clotting. A diagnosis of COVID-19 was marginally associated with an increased risk of circuit clotting (HR = 2.15, 95% CI 0.99-4.68).
Conclusions: In COV + AKI patients, adding systemic heparin to standard regional citrate anticoagulation may prolong CRRT filter patency by reducing clotting risk with a low risk of complications.
Keywords: Acute kidney injury; COVID-19; Citrate; Continuous renal replacement therapy; D-Dimer; Filter lifespan; Heparin.
. 2021 Aug 19;25(1):299.
doi: 10.1186/s13054-021-03729-9.
Continuous renal replacement therapy in COVID-19-associated AKI: adding heparin to citrate to extend filter life-a retrospective cohort study
Eduardo de Oliveira Valle[SUP] 1 [/SUP], Carla Paulina Sandoval Cabrera[SUP] 1 [/SUP], Claudia Coimbra César de Albuquerque[SUP] 1 [/SUP], Giovanio Vieira da Silva[SUP] 1 [/SUP], Márcia Fernanda Arantes de Oliveira[SUP] 1 [/SUP], Gabriel Teixeira Montezuma Sales[SUP] 1 [/SUP], Igor Smolentzov[SUP] 1 [/SUP], Bernardo Vergara Reichert[SUP] 1 [/SUP], Lucia Andrade[SUP] 1 [/SUP], Victor Faria Seabra[SUP] 1 [/SUP], Paulo Ricardo Gessolo Lins[SUP] 1 [/SUP], Camila Eleuterio Rodrigues[SUP] 2 [/SUP]
Affiliations
- PMID: 34412667
- DOI: 10.1186/s13054-021-03729-9
Abstract
Background: Coronavirus disease 2019 (COVID-19) may predispose patients to thrombotic events. The best anticoagulation strategy for continuous renal replacement therapy (CRRT) in such patients is still under debate. The purpose of this study was to evaluate the impact that different anticoagulation protocols have on filter clotting risk.
Methods: This was a retrospective observational study comparing two different anticoagulation strategies (citrate only and citrate plus intravenous infusion of unfractionated heparin) in patients with acute kidney injury (AKI), associated or not with COVID-19 (COV + AKI and COV - AKI, respectively), who were submitted to CRRT. Filter clotting risks were compared among groups.
Results: Between January 2019 and July 2020, 238 patients were evaluated: 188 in the COV + AKI group and 50 in the COV - AKI group. Filter clotting during the first filter use occurred in 111 patients (46.6%). Heparin use conferred protection against filter clotting (HR = 0.37, 95% CI 0.25-0.55), resulting in longer filter survival. Bleeding events and the need for blood transfusion were similar between the citrate only and citrate plus unfractionated heparin strategies. In-hospital mortality was higher among the COV + AKI patients than among the COV - AKI patients, although it was similar between the COV + AKI patients who received heparin and those who did not. Filter clotting was more common in patients with D-dimer levels above the median (5990 ng/ml). In the multivariate analysis, heparin was associated with a lower risk of filter clotting (HR = 0.28, 95% CI 0.18-0.43), whereas an elevated D-dimer level and high hemoglobin were found to be risk factors for circuit clotting. A diagnosis of COVID-19 was marginally associated with an increased risk of circuit clotting (HR = 2.15, 95% CI 0.99-4.68).
Conclusions: In COV + AKI patients, adding systemic heparin to standard regional citrate anticoagulation may prolong CRRT filter patency by reducing clotting risk with a low risk of complications.
Keywords: Acute kidney injury; COVID-19; Citrate; Continuous renal replacement therapy; D-Dimer; Filter lifespan; Heparin.